DOOMS DAY

Discussion in 'Ortho-McNeil' started by Anonymous, Jul 5, 2011 at 4:51 PM.

Tags: Add Tags
  1. Anonymous

    Anonymous Guest

    This just in home office Layoffs coming end September!
     

  2. Anonymous

    Anonymous Guest

    Layoffs in which division? Selling which drug?
     
  3. Anonymous

    Anonymous Guest

    Pricara
     
  4. Anonymous

    Anonymous Guest

    Pricara is gone now..........you mean Retail?
     
  5. Anonymous

    Anonymous Guest

    Yeah right - we just got a major drug approved and all that the people in HQ are talking about is layoffs. I call Bullsh---! Now, go back to the beach you pathetic liar!
     
  6. Anonymous

    Anonymous Guest

    Large-scale layoffs are not happening. Attrition through performance plans and violations is the new way the op cos are downsizing.
     
  7. Anonymous

    Anonymous Guest

    Yep!
     
  8. Anonymous

    Anonymous Guest

    Lawsuit city here they go.
     
  9. Anonymous

    Anonymous Guest

    Don't forget about attrition through people leaving simply because they can not stand working there anymore.
     
  10. Anonymous

    Anonymous Guest

    Just go out there and do your job everyday and you'll be fine.
     
  11. Anonymous

    Anonymous Guest

    yeah go do your job considering its really not a tough one. Go drop samples from 10-2 and sleep the rest of the day!
     
  12. Anonymous

    Anonymous Guest

    That's why I left....couldn't stand the b.s. from management or myself! Felt like I was spewing b.s. all day everyday to customers and my manager. Just couldn't act like I gave a shit anymore. Having a great summer off!
     
  13. Anonymous

    Anonymous Guest

    http://www.ft.com/cms/s/0/469a0c8a-b5d2-11e0-8bed-00144feabdc0.html#ixzz1T57kRd1Y

    J&J plaintiffs shrug off report 11/24, 2011 8:54 pm

    By Andrew Jack and Alan Rappeport

    Plaintiffs threatening legal action against Johnson & Johnson have shrugged off a report from the US healthcare group that dismisses suggestions of systemic or board-level failures behind recent damaging product recalls, aggressive marketing claims and regulatory settlements for paying bribes.

    Their comments followed a filing last week by J&J of findings by a committee of its independent directors that attributed manufacturing quality failures at its McNeil consumer healthcare division to cuts, internal management tensions, frequent executive turnover and distractions caused by the integration of businesses acquired from Pfizer.
    More

    JnJ argues that there was no breach of fiduciary duty but describes mid-level managerial failures and an instance of bribe-giving in Greece in which senior executives were complicit.
    The report, endorsed by the board in mid-July and filed by J&J in response to shareholder lawsuits seeking damages for mismanagement, provides a rare insight into the internal workings of the company.

    Don Haviland, a lawyer representing J&J customers who were denied refunds for recalled Tylenol pain relief products, maintained that the recall problems went all the way to the top.
    “[Chief executive William] Weldon came in with a plan to cut,” he said. “He outsourced too much, cut back on quality control and we’re seeing the results of that.”

    James O’Brien Jr, an attorney representing Oral Cancer Prevention International in a $400m lawsuit against J&J, said that the report showed “an element within Johnson & Johnson that does not seem to follow good corporate governance”, adding: “I don’t think their counsel would let them accept blame publicly. That would just open them up to more claims.”
    Analysing the problems at McNeil that has led regulators to close two sites, the report points to a hiring freeze and concludes that the subsidiary “had a string of successive leaders in a short period of time who may not have had sufficient understanding of what was taking place at the plant level”. It highlights “a lack of attention to product quality by some non-quality personnel” and argues “periodic headcount freezes and an emphasis on production volume may have contributed to this situation. In addition, some equipment was outdated and insufficient.”

    Responding to one of several US legal actions related to marketing of its products, the report describes a “doctor for a day” programme used until 2003 that was developed by the sales force and “not ... management” of Ortho-McNeil, a J&J subsidiary, by which doctors were paid to accompany sales reps selling its TOPAMAX epilepsy treatment on visits to other doctors.

    It rejects claims of “systematic non-compliance” with rules forbidding drug companies from marketing products “off label”, beyond authorised indications.
    But it concedes that “one area of potential improvement” would be for the company to review marketing plans and strategies ahead of programmes targeting doctors likely to prescribe drugs off-label.

    Describing “isolated incidents” of bribes, it concedes that when J&J acquired the De Puy medical device company in 1998, its partner Medec, a Greek distributor, did “make improper payments to surgeons to induce sales”.

    Certain De Puy staff and “potentially” its worldwide chairman maintained the corporate relationship with Medec “while keeping the sales practice at arms length” until 2005.
    J&J’s medical devices chairman, who was said to have ultimate responsibility for De Puy through the reporting chain, retired on the same day the company formally notified the authorities of the practice in 2007, but the report concluded that it was not in the interests of the company to pursue potential claims for breach of fiduciary duty against either executive.

    It says the company’s Polish division also made sponsorship payments to doctors “intended to influence pending tender offers” until an inquiry in 2006; and in Romania until 2007 it found staff had arranged cash, gifts and travel “in exchange for prescriptions for select J&J products”.

    J&J said in a statement: “The company’s management takes the shareholder concerns and criticisms very seriously and appreciates that the special committee has given these matters careful consideration.”

    The Financial Times Limited 2011.